Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder

Table 3 Behavioral assessment*

Assessment	Baseline	Week 4	Week 8
ADHD SC-4 Inattention	18.11 ± 5.37	10.56 ± 5.46^a	9.78 ± 6.91^a
median	17	9	10
ADHD SC-4 Hyperactivity	11.33 ± 4.53	7.67 ± 5.96	5.22 ± 3.99^a
median	10	6	4
ADHD SC-4 Oppositional/defiant	10.11 ± 6.79	5.44 ± 3.88^b	5.22 ± 3.56^b
median	11	7	5
ADHD SC-4 Conduct disorder	5.22 ± 6.26	0.89 ± 0.93^b	1.11 ± 2.26^b
median	4	1	0
CPRS-Oppositional behavior	8.67 ± 4.58	5.38 ± 3.11	4.89 ± 2.93^a
median	7	5.5	6
CPRS- Cognitive problems/inattention	11.56 ± 5.13	7.00 ± 3.89^b	8.44 ± 6.48
median	12	8.5	8
CPRS- Hyperactivity	5.89 ± 3.79	2.63 ± 2.39	3.22 ± 4.49
median	6	3	2
CPRS- ADHD index	22.67 ± 9.03	13.63 ± 6.37^a	15.44 ± 9.49^b
median	22	13	14
Clinical Severity of Illness	4.38 ± 0.74	3.56 ± 0.73	3.33 ± 1.12^c
median	4.5	3	3

* Values are mean ± SD and medians (n = 9). ADHD SC-4, Attention Deficit Hyperactivity Disorder Symptom Checklist 4. CPRS, Conners' Parents Rating Scale ^a p < 0.01, ^b p < 0.05 using Wilcoxon signed rank test to compare to baseline; ^c p = 0.08 using Friedman test to compare to baseline.

ISSN: 1475-2891